Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Paclitaxel in AR-Positive Triple-Negative Breast Cancer
NCT02689427Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2016
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2016; status: completed.
02
Drugs
enzalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02689427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689427.